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Abstract 
Objectives. The EULAR/ACR 2019 Classification Criteria for systemic lupus erythematosus (SLE) 
have been validated with high sensitivity and specificity. We evaluated the performance of the 
new criteria with regard to disease duration, sex, and race/ethnicity, and compared its 
performance against the SLICC 2012 and ACR 1982/1997 criteria. 
 
Methods. Twenty-one SLE centers from 16 countries submitted SLE cases and mimicking 
controls to form the validation cohort. The sensitivity and specificity of the EULAR/ACR 2019, 
SLICC 2012 and ACR 1982/1997 criteria were evaluated.   
 
Results. The cohort consisted of female (n=1098), male (n=172), Asian (n=118), Black (n=68), 
Hispanic (n=124) and White (n=941) patients; with an SLE duration of 1-<3 years (n=196) and 5 
years (n=879). Among patients with 1-<3 years disease duration, the EULAR/ACR criteria had 
better sensitivity than the ACR criteria (97% versus 81%). The EULAR/ACR criteria performed 
well in men (sensitivity 93%, specificity 96%) and women (sensitivity 97%, specificity 94%). 
Among women, the EULAR/ACR criteria had better sensitivity than the ACR criteria (97% versus 
83%) and better specificity than the SLICC criteria (94% versus 82%). Among White patients, the 
EULAR/ACR criteria had better sensitivity than the ACR criteria (95% versus 83%) and better 
specificity than the SLICC criteria (94% versus 83%). The EULAR/ACR criteria performed well 
among Black patients (sensitivity of 98%, specificity 100%), and had better sensitivity than the 
ACR criteria among Hispanic patients (100% versus 86%) and Asian patients (97% versus 77%).  
 
Conclusions. The EULAR/ACR 2019 criteria perform well among patients with early disease, 
men, women, White, Black, Hispanic and Asian patients. These criteria have superior sensitivity 
than the ACR criteria and/or superior specificity than the SLICC criteria across many subgroups. 
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INTRODUCTION 
Classification criteria constitute a cornerstone of clinical research in Rheumatology as they 
facilitate identification of homogeneous groups of patients for inclusion into observational 
studies and clinical trials.[1] The European League Against Rheumatism (EULAR)/ American 
College of Rheumatology (ACR) 2019 classification criteria for SLE were developed through an 
international collaboration using both data-driven and expert-based consensus-finding 
methods.[2-10] The new criteria define the presence of one or more results for antinuclear 
antibody (ANA) tests at a titer of ≥1:80 (or an equivalent positive test) as an entry requirement. 
The subsequent criteria are grouped into seven clinical domains (constitutional, hematologic, 
neuropsychiatric, mucocutaneous, serosal, musculoskeletal and renal) and 3 immunologic 
domains (antiphospholipid antibodies, hypocomplementemia, SLE-specific antibodies). Related 
organ system criteria are clustered hierarchically and numerically weighted to form an additive 
point system. A patient can be classified as having SLE if the ANA entry criterion is fulfilled, at 
least one clinical criterion is present, and the accumulated points of all domains total 10 or 
more. One attribution rule for all items replaced exclusion criteria, stating that items should 
only be counted if there was no explanation more likely than SLE. Novel features of the 
classification system are the inclusion of fever, in the absence of infection or other causes, as a 
criterion to assist in classification of earlier disease; and separation of class II and V from class III 
and IV lupus nephritis as distinct criteria. Class III or IV lupus nephritis was found to be more 
influential in the classification of an ANA positive individual and given 10 points, thereby 
forming the only singular sufficient criterion for classification of SLE in the presence of ANA.  
 
In the validation cohort, the new criteria had a sensitivity of 96% and a specificity of 93%. This 
led to the endorsement of the new criteria by both EULAR and ACR.[11, 12] Through the criteria 
development and review processes, investigators and reviewers questioned the operating 
characteristics of the new criteria in subsets of SLE patients.[13] Indeed, there is a need for 
criteria that perform well in early disease for more timely inclusion in clinical trials and research 
studies.[14] Furthermore, differences in SLE disease expression have been described between 
sexes and across ethnicities which may impact the performance of classification criteria in these 
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groups of patients.[15-17] Therefore, the objectives of this study were to evaluate the 
sensitivity and specificity of the EULAR/ACR 2019 classification criteria in early disease, across 
sexes and ethnicities.[11, 12] We also comparatively evaluated the operating characteristics of 
the EULAR/ACR 2019 classification criteria against the ACR 1982/1997[18, 19] and the Systemic 
Lupus International Collaborating Clinics (SLICC) 2012[20] classification criteria for SLE. 
 
METHODS 
SLE cases and controls. Twenty-one SLE expert centers from 16 countries submitted between 
20 and 100 SLE cases and the same number of SLE mimicking controls each to form the 
validation cohort for the EULAR/ACR 2019 classification criteria. The investigators from these 
centers had not been part of the steering committee, the nominal group technique[7] nor the 
multicriteria decision analysis[10] of the project and were thus unaware of the new criteria 
form or content. The 100 case and control limit per center was used to preclude any one center 
from dominating the cohort. Data on all cases and controls, including demographic data and 
SLE duration, were collected using a standardized form.  
 
Data administration. Cases and control diagnoses (SLE or not SLE) were made by the submitting 
investigator and were independently verified by 3 SLE experts. Previous sets of classification 
criteria were not considered when selecting cases nor controls. Data were double entered into 
a computerized database. Data quality was maintained using logic and range checks. Data 
queries were reconciled by interrogation of the submitting investigator. Research ethics board 
approval and patient consent was obtained by the data coordinating center and all submitting 
centers, as required locally. 
 
SLE subsets. Disease duration was calculated from date of physician diagnosis to date of data 
submission. Data on sex were self-reported as male or female. Data on gender were not 
collected. Data on ethnicity, self-reported and verified by the investigators, were collected from 
the medical records, and categorized as White, Black, Hispanic (Latin American heritage) and 
Asian.  
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Statistical analysis. Sensitivity and specificity for each of the classification criteria sets among 
subsets of SLE patients were estimated with their corresponding 95% confidence intervals (CI). 
Non-overlapping confidence intervals denotes statistically significant differences. Statistical 
analyses were performed using R, version 3.4.0 (The R Foundation of Statistical Computing). 
 
 
RESULTS 
Cohort. Cases and controls were submitted from centers in Austria, Canada, Croatia, France, 
Germany, Greece, Hong Kong, Hungary, Japan, Italy, Mexico, Portugal, Spain, Turkey, United 
Kingdom, and United States of America. The validation cohort (n=1270) consisted of female 
(n=1,098 (86%)) and male (n=172 (14%)) patients; Asian (n=118 (9%)), Black (n=68 (5%)), 
Hispanic (n=124 (10%)) and White (n=941 (74%)) patients; and patients with an SLE duration of 
less than 1 year (n=34 (3%)), 1 to less than 3 years (n=196 (16%)), 3 to less than 5 years (n=157 
(12%)), and 5 or more years (n=879 (69%)). The 5 subjects who were Arab and 13 subjects who 
had an ethnicity categorized as ‘Other’ were excluded from the ethnicity analyses as their 
numbers were so small. Four subjects had missing disease duration data.  
 
 
Operating characteristics. As shown in Table 1, which includes 95% CIs, the EULAR/ACR 2019 
criteria performed well among patients with early disease defined as 1 to less than 3 years of 
disease duration (sensitivity 97%, specificity 96%) and among patients with 3 to less than 5 
years disease duration (sensitivity 96%, specificity 99%). The EULAR/ACR 2019 criteria also 
performed well among patients with established disease defined as 5 or more years disease 
duration (sensitivity 96%, specificity 93%). They also perform well in men (sensitivity 93%, 
specificity 96%), women (sensitivity 97%, specificity 94%), and in all the race/ethnicity groups 
examined. Table 1.  
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Among women, the EULAR/ACR 2019 criteria had better sensitivity than the ACR 1982/1997 
criteria (97% (95%CI 95-98%) versus 83% (95%CI 80-86%) and better specificity than the SLICC 
criteria (94% (95%CI 91-96%) versus 82% (95%CI 79-86%). (Figure 1.) 
 
Among White patients, the EULAR/ACR 2019 criteria had better sensitivity than the ACR 
1982/1997 criteria (95% (95%CI 93-97%) versus 83% (95%CI 79-86%) and better specificity than 
the SLICC criteria (94% (95%CI 91-96%) versus 83% (95%CI 80-87%). (Figure 2.) The EULAR/ACR 
2019 criteria performed well among Black patients with a sensitivity of 98% (95%CI 90-100%) 
and specificity 100% (95%CI 74-100%). The 95% confidence intervals around these estimates 
are larger due to the smaller sample size. The EULAR/ACR 2019 criteria had better sensitivity 
than the ACR 1982/1997 criteria among Hispanic patients (100% % (95%CI 95-100%) versus 86% 
(95%CI 76-93%) and Asian patients (97% (95%CI 91-100%) versus 77% (95%CI 65-86%). 
 
In patients with 1 to less than 3 years disease duration, the EULAR/ACR 2019 criteria had better 
sensitivity than the ACR 1982/1997 criteria (97% (95%CI 92-99%) versus 81% (95%CI 72-88%). 
Among patients with 5 or more years disease duration, the EULAR/ACR 2019 criteria had better 
sensitivity than the ACR 1982/1997 criteria (96% (95%CI 94-98%) versus 84% (95%CI 80-87%) 
and better specificity than the SLICC criteria (93% (95%CI 89-95%) versus 81% (95%CI 76-85%). 
Among SLE patients with less than 3 years disease duration (early disease), oral ulceration, non-
scaring alopecia and pleural/pericardial effusions occurred more frequently. Among SLE 
patients with a disease duration of 5 or more years, acute cutaneous lupus, arthritis, seizures, 
pericarditis, leukopenia and class III or IV nephritis occurred more frequently. Table 3. 
 
The operating characteristics of the ACR 1982/1997 and SLICC 2012 reported in other studies 
are summarized in Table 2 and are generally consistent with their performance in the present 
study. 
 
DISCUSSION 
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The EULAR/ACR 2019 criteria have strong operating characteristics (sensitivity and specificity) 
across subsets of SLE patients, specifically among male and female, White, Black, Hispanic and 
Asian patients. Importantly, the new criteria perform well among patients with early disease. 
Indeed, this was one of the reasons to develop new classification criteria. Furthermore, the new 
criteria confer improved performance compared to previous sets of SLE classification criteria, 
retaining their superior sensitivity compared to the ACR criteria, as well as their superior 
specificity compared to the SLICC criteria in many of these groups. There was no subset of 
patients identified in which the new criteria performed substantially worse than previous 
criteria. The EULAR/ACR 2019 SLE criteria reflect the current thinking of the international SLE 
community about how SLE is to be classified and reduce the potential risk of misclassification of 
ANA positive patients. 
 
Our demonstration that the EULAR/ACR 2019 SLE criteria perform well in early disease is an 
important contribution to the field. We tested different definitions of early disease (less than 1 
year, 1 to less than 3 years, 3 to less than 5 years disease duration), and in all of our definitions, 
the new criteria performed well. The validity of classification criteria for early disease allows for 
more timely inclusion in clinical trials and observational studies. It is hoped that intervention in 
those early in their disease course may prevent complications and irreversible damage.[14] 
Identifying when the disease started can be challenging as a patients may have symptoms or 
even full SLE for a period of time before being diagnosed. We note that there is no standardized 
definition of ‘early’ SLE. However, other definitions of early, very early, latent or incomplete 
disease (i.e. other terms used to describe patients with some symptoms and signs of SLE) have 
been proposed.[14, 21] In this study, disease duration was calculated from the date of physician 
diagnosis to date of data submission. While such data are not available from the EULAR/ACR 
patient data set, another very important stage of the disease is from first sign or symptom to 
diagnosis. We encourage investigators to test the performance of the new classification criteria 
using these alternative definitions of ‘early’ disease. It should be noted, that in our study, the 
diagnosis of all cases and controls was verified by 3 independent reviewers from different 
centers, thereby reducing potential bias of a submitting center. If investigators test alternative 
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definitions of early disease, we encourage investigators to submit cases and controls for 
independent verification. 
 
 
The operating characteristics of the ACR 1982/1997 and SLICC 2012 criteria in this study were 
similar to those reported by others.[22, 23] Among Asian patients, Oku et al reported sensitivity 
and specificity of the ACR criteria (88% and 85%, respectively) and the SLICC criteria (99% and 
80%, respectively).[24] Among patients with less than 5 years disease duration in the 
Portuguese and Spanish National Registries (Reuma.pt and RELESSER cohorts, respectively), 
Ines et al reported a sensitivity of 76% for the ACR criteria and 89% for the SLICC criteria.[23] 
Similarly among patients with >5 years disease duration, they reported a sensitivity of 89% for 
the ACR criteria and 90% for the SLICC criteria.[23] In an international early SLE cohort, Mosca 
et al reported similar sensitivity and specificity as Ines et al for the ACR criteria (66% and 97%, 
respectively) and the SLICC criteria (84% and 82%, respectively).[5] Thus, the performance 
characteristics of previous iterations of SLE classification criteria in our study are similar to 
those in other cohorts and therefore further support the generalizability of our conclusions.  
 
One potential limitation of this study is the numbers of patients from non-White ethnicities. 
Although we had sufficient numbers of patients to estimate performance in multiple 
subgroups, larger numbers of patients would improve the precision of our estimates. This is 
particularly true of the Black patient subset. The underrepresentation of Black patients in this 
cohort may be partially explained by a low number of Black patients in European cohorts. It 
may also reflect a sampling bias that occurred by chance in the North American cohorts. There 
is a need for more Black patients with SLE and control group diseases to refine the precision of 
our estimates evaluating the operating characteristics of the new criteria in this group. 
Moreover, there were only three centers from Asia and none from Africa or South America 
contributing patients to this analysis. Future collaborative studies by EULAR and ACR should 
consider recruiting a broader spectrum of referral centers from these regions to avoid similar 
 13 
limitations. Investigators are encouraged to test these new criteria in larger numbers of Black 
patients and other race/ethnic groups as well as SLE centers worldwide.  
 
Secondly, these subgroup analyses were conducted using the same cohort to validate the new 
criteria. The observed excellent operating characteristics across subgroups is similar in 
magnitude to the operating characteristics observed in the whole cohort. Others are 
encouraged to test the performance characteristics in independent cohorts.[25] Two cautionary 
notes are made to investigators who embark on comparative evaluation of the new criteria to 
previous classification criteria. The new classification criteria are not diagnostic criteria. Neither 
EULAR nor ACR endorse the development or validation of diagnostic criteria. [26]  It is therefore 
inappropriate to evaluate these criteria as diagnostic criteria.[26] These criteria have been 
endorsed for identifying SLE patients for research studies and will facilitate comparisons across 
studies. The diagnosis of SLE remains in the domain of the appropriately trained physician. 
These criteria should have no treatment implications for patients.[26]  Most importantly, failure 
to fulfil these criteria should not be used by payers to deny appropriate therapy to patients, 
which in the case of the EULAR/ACR criteria prominently applies to patients who never had 
positive ANA. 
 
A critical feature of the reliable application of these classification criteria is appropriate 
attribution. A criterion should not be counted if there is a more likely explanation than SLE. The 
requirements to use the precise definition of criteria and ascertain correct attribution for each 
criterion may reduce the opportunity of testing the criteria performance in pre-existing 
databases. These requirements are necessary for achieving specificity and facilitating reliable 
application of the criteria between sites and between studies. 
 
In conclusion, the EULAR/ACR 2019 SLE classification criteria perform well among patients with 
early disease. The new SLE classification criteria also perform well in both sexes, and among 
White, Black, Hispanic and Asian patients. More work is needed to improve the precision of the 
estimates among Black and evaluate criteria performance in other race/ethnicities. Overall, the 
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new criteria provide added value compared to previous versions of SLE classification. The 
EULAR/ACR 2019 SLE criteria provide early and accurate classification of SLE across various SLE 
patient subpopulations. 
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Table 1. Sensitivity and Specificity of SLE Classification Criteria Across Sexes, Ethnicities and 
Disease Duration 
 
 
Sensitivity Specificity 
  
95% CI 
  
95% CI 
 
 
ACR 
1982/1997 
Criteria 
SLICC 2012 
Criteria 
EULAR/ACR 
2019 Criteria 
ACR 
1982/1997 
Criteria 
SLICC 2012 
Criteria 
EULAR/ACR 
2019 Criteria 
Sex 
      
Women 0.83 0.97 0.97 0.93 0.82 0.94 
n=1,098 0.80-0.86 0.95-0.98 0.95-0.98 0.91-0.95 0.79-0.86 0.91-0.96 
Men 0.78 0.94 0.93 0.94 0.9 0.96 
n=172 0.68-0.87 0.87-0.98 0.86-0.98 0.87-0.98 0.82-0.96 0.90-0.99 
Disease Duration 
< 1 year 0.56 0.89 0.89 0.92 0.92 0.92 
n=34 0.21-0.86 0.52-0.99 0.52-1.00 0.74-0.99 0.74-0.99 0.74-0.99 
1 to <3 years 0.81 0.98 0.97 0.95 0.88 0.96 
n=196 0.72-0.88 0.93-1.00 0.92-0.99 0.88-0.98 0.80-0.94 0.90-0.99 
3 to <5 years 0.81 0.91 0.96 0.94 0.89 0.99 
n=157 0.70-0.90 0.82-0.97 0.88-0.99 0.87-0.98 0.80-0.94 0.94-1.00 
≥5 years 0.84 0.97 0.96 0.93 0.81 0.93 
n=879 0.80-0.87 0.96-0.99 0.94-0.98 0.90-0.95 0.76-0.85 0.89-0.95 
Ethnicity 
White 0.83 0.96 0.95 0.93 0.83 0.94 
n=941 0.79-0.86 0.94-0.97 0.93-0.97 0.90-0.95 0.80-0.87 0.91-0.96 
Black 0.82 0.98 0.98 1 0.92 1 
n=68 0.70-0.91 0.90-1.00 0.90-1.00 0.74-1.00 0.62-1.0 0.74-1.00 
Hispanic 0.86 1 1 0.96 0.78 0.96 
n=124 0.76-0.93 0.95-1.00 0.95-1.00 0.87-1.00 0.65-0.89 0.87-1.00 
Asian 0.77 0.99 0.97 0.93 0.91 0.91 
n=118 0.65-0.86 0.93-1.00 0.91-1.00 0.82-0.99 0.79-0.98 0.79-0.98 
 
ACR American College of Rheumatology, SLICC Systemic Lupus International Collaborating 
Clinics, EULAR European League Against Rheumatism 
 
Non-overlapping confidence intervals indicates statistical significance 
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Table 2. Summary of previously published operating characteristics of SLE classification criteria 
among patient subsets 
 
Reference Subset ACR Criteria SLICC Criteria 
  Sensitivity % 
(95%CI) 
Specificity % 
(95%CI) 
Sensitivity % 
(95%CI) 
Specificity % 
(95%CI) 
Ethnicity 
Oku et al. 
2018 
Asian 88% (83 - 92%) 85% (80 - 89%) 99% (96 - 100%) 80% (75 - 85%) 
Disease duration 
Ighe et al. 
2015 
0 – 4 years ACR 1982 
60% (44 - 75%) 
NR 89% (73- 97%) NR 
 5 – 9 years 89% (77 - 96%) NR 89% (77 - 96%) NR 
 10 – 14 years 76% (62 - 86%) NR 88 % (75 - 95%) NR 
 15 – 19 years 69% (54 - 81%) NR 84% (71 - 93%) NR 
 ≥20 years 86% (75 - 92%) NR 97% (89 - 100%) NR 
Ighe et al. 
2015 
0 – 4 years ACR 1997 
82% (65 - 92%) 
NR SLICC* 
80% (64 - 91%) 
NR 
 5 – 9 years 94% (84 - 99%) NR 84% (71 - 92%) NR 
 10 – 14 years 91% (79 - 98%) NR 84% (70 - 92%)  NR 
 15 – 19 years 86% (72 - 94%) NR 80% (66 - 90%) NR 
 ≥20 years 91 % (82 - 97%) NR 94% (85 - 98%) NR 
Ines et al. 
2015 
Any duration ACR 1997 
86% 
NR 93% NR 
 ≤5 years 76% NR 89% NR 
 >5 to ≤10 years 82% NR 90% NR 
 >10 to ≤15 years 88% NR 95% NR 
 >20 years 94% NR 97% NR 
Mosca et al. 
2019 
Early cohort,  
At diagnosis 
66% 92% 84% 82% 
 
*SLICC-12 with a requirement for involvement of at least two organ systems for SLE diagnosis 
NR Not reported 
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Table 3. Frequency of criteria in early and established SLE 
 
Criteria Early Disease 
<3 years duration 
Established disease 
>5 years duration 
Constitutional    
   Fever 12.6% 15.1% 
 22 
 
 
 
 
 
 
 
Figure 1. Forest plot comparing the sensitivity and specificity of SLE classification criteria in 
Women. 
 
Mucocutaneous   
   Non-scarring alopecia                                      
   Oral ulcers                                                                           
Subacute cutaneous or discoid lupus            
   Acute cutaneous lupus                                                         
29.4% 
25.2% 
11.1% 
34.2% 
26.4% 
17.9% 
11.3% 
44.5% 
Arthritis 28.7% 69.3% 
Neurologic   
   Delirium 0% 0.6% 
   Psychosis 2.1% 1.4% 
   Seizure 2.1% 5.6% 
Serositis   
   Pleural or pericardial effusion 18.9% 10.5% 
   Acute pericarditis 3.5% 6.8% 
Hematologic   
   Leukopenia 39.9% 44.5% 
   Thrombocytopenia 41.3% 35.9% 
   Autoimmune hemolysis 18.9% 19.6% 
Renal   
   Proteinuria >0.5g/24h 9.8% 7.2% 
Renal biopsy Class II or V lupus  
nephritis  
7.0% 8.9% 
Renal biopsy Class III or IV lupus 
nephritis  
16.1% 24.7% 
Antiphospholipid antibodies   
   Anti-cardiolipin antibodies or 
   Anti-β2GP1 antibodies or 
   Lupus anticoagulant 
26.6% 28.0% 
Complement proteins   
 Low C3 or low C4 21.7% 24.7% 
 Low C3 and low C4 49.7% 46.2% 
Highly specific antibodies    
 Anti-dsDNA antibody or 83.2% 78.3% 
 Anti-Smith antibody   
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Footnote. Cl 95% confidence interval. All women (n=1098) were included in this analysis 
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Figure 2. Forest plot comparing the sensitivity and specificity of SLE classification criteria in 
White subjects 
 
Footnote. Cl 95% confidence interval. All White subjects (n=941) were included in this analysis. 
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Key Messages 
 
What is already known about this subject? 
Classification criteria are needed to identify homogeneous groups of patients for inclusion into 
clinical trials and observational studies. The 2019 EULAR/ACR Classification Criteria have 
excellent sensitivity and specificity. 
 
What does this study add? 
The 2019 EULAR/ACR criteria perform well among patients with early disease, men, women, 
White, Black, Hispanic and Asian patients.  
 
How might this impact on clinical practice? 
These criteria have superior sensitivity than the ACR criteria and/or superior specificity than the 
SLICC criteria across many subgroups. They can be used as inclusion criteria for study of novel 
treatments in systemic lupus erythematosus. 
 
 
